US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

7.62

+0.14001.87%

Post-market: 7.640.0200+0.26%19:30 EDT

Volume:1.22M

Turnover:9.17M

Market Cap:342.89M

PE:-3.51

High:7.75

Open:7.40

Low:7.12

Close:7.48

52wk High:54.97

52wk Low:4.01

Shares:45.00M

Float Shares:16.73M

Volume Ratio:1.13

T/O Rate:7.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1683

EPS(LYR):-1.8835

ROE:-32.34%

ROA:-21.54%

PB:1.29

PE(LYR):-4.05

Loading ...

Overview Company News Filings

Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics director Peter A. Thompson sells 292,952 shares for $13.37 million

OrbiMed Advisors disposes 292,952 Sionna Therapeutics shares for $13.5 million

Sionna Therapeutics Initiated at Outperform by Wedbush

Sionna Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $53

THOMSON REUTERS

Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target

MT Newswires Live

Is Sionna Therapeutics (SION) Stock Overvalued After Its Strong 1 Year Run And 6x P/B Multiple

Simply Wall St.

Sionna Therapeutics initiated with an Outperform at Wedbush

Sionna Therapeutics Is Maintained at Buy by Jones Trading

Sionna Therapeutics price target raised to $63 from $52 at JonesResearch

Sionna Therapeutics announces annual shareholder meeting

Sionna Therapeutics Price Target Maintained With a $58.00/Share by BTIG

Sionna Therapeutics completes enrollment in Phase 2a PreciSION CF trial of SION-719

Sionna Therapeutics Inc: Anticipates Data From Precision CF Trial in Summer of 2026.

THOMSON REUTERS

Sionna Therapeutics Completes Enrollment in Precision CF Phase 2a Trial Evaluating Nbd1 Stabilizer, Sion-719, Added to Standard of Care in Participants With Cystic Fibrosis

THOMSON REUTERS

Sionna director Peter A. Thompson disposes of USD 2.5 million common shares

OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $2.5 million

Sionna director Peter A. Thompson disposes of common shares worth $23.2 million

OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $23.1 million

Assessing Sionna Therapeutics (SION) Valuation After Recent Trading And Cystic Fibrosis Pipeline Expectations

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/SION/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SION","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SION\",,,,,undefined,":{"symbol":"SION","market":"US","secType":"STK","nameCN":"Sionna Therapeutics","latestPrice":7.62,"timestamp":1789070400000,"preClose":7.48,"halted":0,"volume":1222617,"hourTrading":{"tag":"盘后","latestPrice":7.64,"preClose":7.62,"latestTime":"19:30 EDT","volume":18381,"amount":139913.3744,"timestamp":1789083007612,"change":0.02,"changeRate":0.002625,"amplitude":0.027559},"delay":0,"changeRate":0.01871657754010691,"floatShares":16725500,"shares":44998073,"eps":-2.16827,"marketStatus":"Closed","change":0.14,"latestTime":"09-10 16:00:00 EDT","open":7.4,"high":7.75,"low":7.12,"amount":9168375.540192,"amplitude":0.084225,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.16827,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"listingDate":1738904400000,"exchange":"NASDAQ","adjPreClose":7.48,"preHourTrading":{"tag":"盘前","latestPrice":7.4,"preClose":7.48,"latestTime":"09:29 EDT","volume":2961,"amount":22038.566067,"timestamp":1789046970089,"change":-0.08,"changeRate":-0.010695,"amplitude":0.061497},"postHourTrading":{"tag":"盘后","latestPrice":7.64,"preClose":7.62,"latestTime":"19:30 EDT","volume":18381,"amount":139913.3744,"timestamp":1789083007612,"change":0.02,"changeRate":0.002625,"amplitude":0.027559},"volumeRatio":1.129389,"impliedVol":1.7377,"impliedVolPercentile":0.6098},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SION\",,,,,undefined,":{"symbol":"SION","floatShares":16725500,"roa":"-21.54%","roe":"-32.34%","lyrEps":-1.883481,"volumeRatio":1.129389,"shares":44998073,"dividePrice":0,"high":7.75,"amplitude":0.084225,"preClose":7.48,"low":7.12,"week52Low":4.01,"pbRate":"1.29","week52High":54.97,"institutionHeld":0,"latestPrice":7.62,"eps":-2.16827,"divideRate":0,"volume":1222617,"delay":0,"ttmEps":-2.16827,"open":7.4,"prevYearClose":41.14,"prevWeekClose":7.18,"prevMonthClose":6.03,"prevQuarterClose":43.99,"fiveDayClose":7.31,"twentyDayClose":6.25,"sixtyDayClose":36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SION\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"SION","fiscalQuarterEnding":"2026/06","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.66},{"market":"US","date":"2026-05-12","symbol":"SION","fiscalQuarterEnding":"2026/03","expectedEps":-0.52,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2026-03-02","symbol":"SION","fiscalQuarterEnding":"2025/12","expectedEps":-0.61,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1772427600000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2025-11-05","symbol":"SION","fiscalQuarterEnding":"2025/09","expectedEps":-0.52,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2025-08-11","symbol":"SION","fiscalQuarterEnding":"2025/06","expectedEps":-0.68,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-0.41}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SION\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SION\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.0909,"hold":0.9091,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.9091,"analysts":11,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SION\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SION","date":"2026-09-09","current":-3.514322,"percent":0.952141,"low":-28.087165,"twenty":-23.984129,"median":-18.377353,"eighty":-10.172905,"high":-2.089233,"avg":-17.29209,"sd":7.133335,"marketCap":330050512},"quantilePoints":[{"date":"2025-02-07","current":-13.261013,"twenty":-12.252025,"median":-10.738543,"eighty":-9.22506,"marketCap":765372600},{"date":"2025-02-14","current":-14.940741,"twenty":-16.115077,"median":-14.940741,"eighty":-13.535074,"marketCap":862319796},{"date":"2025-02-21","current":-15.365065,"twenty":-15.365065,"median":-14.763927,"eighty":-14.631317,"marketCap":886810118},{"date":"2025-02-28","current":-11.280197,"twenty":-15.101402,"median":-14.760244,"eighty":-13.045594,"marketCap":651047865},{"date":"2025-03-07","current":-11.960372,"twenty":-15.059369,"median":-14.631317,"eighty":-11.310767,"marketCap":690304817},{"date":"2025-03-14","current":-13.068521,"twenty":-15.036515,"median":-13.072343,"eighty":-11.387191,"marketCap":754262771},{"date":"2025-03-21","current":-10.607665,"twenty":-14.940741,"median":-12.594692,"eighty":-11.280197,"marketCap":612232003},{"date":"2025-03-28","current":-8.569094,"twenty":-14.763927,"median":-12.189644,"eighty":-10.607665,"marketCap":528610240},{"date":"2025-04-04","current":-8.304439,"twenty":-14.75656,"median":-11.44833,"eighty":-8.654927,"marketCap":512284214},{"date":"2025-04-11","current":-5.47907,"twenty":-14.719724,"median":-11.345158,"eighty":-8.304439,"marketCap":337992858},{"date":"2025-04-17","current":-7.152833,"twenty":-14.648998,"median":-11.146455,"eighty":-7.438946,"marketCap":441243940},{"date":"2025-04-25","current":-9.012569,"twenty":-13.535074,"median":-10.607665,"eighty":-7.830921,"marketCap":555967364},{"date":"2025-05-02","current":-9.227154,"twenty":-13.113134,"median":-10.157913,"eighty":-8.049798,"marketCap":569204682},{"date":"2025-05-09","current":-8.991111,"twenty":-13.07005,"median":-9.363058,"eighty":-8.189398,"marketCap":554643632},{"date":"2025-05-16","current":-8.935031,"twenty":-13.050179,"median":-9.227154,"eighty":-8.189398,"marketCap":592598052},{"date":"2025-05-23","current":-8.649163,"twenty":-12.684872,"median":-9.227154,"eighty":-8.258154,"marketCap":573638442},{"date":"2025-05-30","current":-9.380453,"twenty":-12.498397,"median":-9.212848,"eighty":-8.290133,"marketCap":622139770},{"date":"2025-06-06","current":-10.656886,"twenty":-12.42503,"median":-9.227154,"eighty":-8.395596,"marketCap":706796635},{"date":"2025-06-13","current":-11.295102,"twenty":-12.251212,"median":-9.28738,"eighty":-8.459628,"marketCap":749125067},{"date":"2025-06-20","current":-9.792634,"twenty":-12.067794,"median":-9.313972,"eighty":-8.462287,"marketCap":649476883},{"date":"2025-06-27","current":-9.859115,"twenty":-11.920631,"median":-9.377129,"eighty":-8.491142,"marketCap":653886095},{"date":"2025-07-03","current":-14.087299,"twenty":-12.050418,"median":-9.569923,"eighty":-8.540482,"marketCap":934311959},{"date":"2025-07-11","current":-13.921097,"twenty":-12.562594,"median":-9.646376,"eighty":-8.576247,"marketCap":923288929},{"date":"2025-07-18","current":-12.185946,"twenty":-12.955414,"median":-9.792431,"eighty":-8.606288,"marketCap":808208504},{"date":"2025-07-25","current":-12.724441,"twenty":-12.981363,"median":-9.952188,"eighty":-8.61201,"marketCap":843923119},{"date":"2025-08-01","current":-11.142196,"twenty":-12.981363,"median":-10.527086,"eighty":-8.61201,"marketCap":738983880},{"date":"2025-08-08","current":-11.487897,"twenty":-12.719123,"median":-10.607665,"eighty":-8.619441,"marketCap":761911781},{"date":"2025-08-15","current":-12.17004,"twenty":-12.719123,"median":-10.776552,"eighty":-8.650316,"marketCap":922963698},{"date":"2025-08-22","current":-13.817157,"twenty":-12.981363,"median":-10.951574,"eighty":-8.660649,"marketCap":1047879398},{"date":"2025-08-29","current":-14.969557,"twenty":-13.185819,"median":-11.135548,"eighty":-8.685971,"marketCap":1135276247},{"date":"2025-09-05","current":-13.421384,"twenty":-13.261013,"median":-11.264381,"eighty":-8.6957,"marketCap":1017864318},{"date":"2025-09-12","current":-13.849168,"twenty":-13.582045,"median":-11.295102,"eighty":-8.81229,"marketCap":1050307088},{"date":"2025-09-19","current":-13.520327,"twenty":-13.543608,"median":-11.380538,"eighty":-8.928383,"marketCap":1025368088},{"date":"2025-09-26","current":-16.005553,"twenty":-13.817157,"median":-11.448008,"eighty":-8.935031,"marketCap":1213845132},{"date":"2025-10-03","current":-17.053189,"twenty":-13.934393,"median":-11.481249,"eighty":-8.974919,"marketCap":1293296813},{"date":"2025-10-10","current":-16.50027,"twenty":-14.087299,"median":-11.594266,"eighty":-8.991111,"marketCap":1251363982},{"date":"2025-10-17","current":-19.043698,"twenty":-14.329335,"median":-11.773765,"eighty":-9.012569,"marketCap":1444255008},{"date":"2025-10-24","current":-23.047996,"twenty":-14.678547,"median":-11.960372,"eighty":-9.101233,"marketCap":1747936990},{"date":"2025-10-31","current":-22.122584,"twenty":-14.777491,"median":-12.128534,"eighty":-9.127014,"marketCap":1677754672},{"date":"2025-11-07","current":-21.722088,"twenty":-15.059369,"median":-12.17004,"eighty":-9.148473,"marketCap":1535230307},{"date":"2025-11-14","current":-22.656643,"twenty":-15.557397,"median":-12.201274,"eighty":-9.173508,"marketCap":1601280913},{"date":"2025-11-21","current":-24.588899,"twenty":-16.50027,"median":-12.318908,"eighty":-9.207602,"marketCap":1737845004},{"date":"2025-11-28","current":-27.51254,"twenty":-16.690008,"median":-12.434201,"eighty":-9.211799,"marketCap":1944476293},{"date":"2025-12-05","current":-25.813923,"twenty":-17.070649,"median":-12.542534,"eighty":-9.224293,"marketCap":1824424853},{"date":"2025-12-12","current":-26.344347,"twenty":-17.43383,"median":-12.644664,"eighty":-9.227154,"marketCap":1861913035},{"date":"2025-12-19","current":-27.916672,"twenty":-18.615331,"median":-12.828464,"eighty":-9.244321,"marketCap":1973038717},{"date":"2025-12-26","current":-27.799853,"twenty":-20.840976,"median":-13.015231,"eighty":-9.271873,"marketCap":1964782391},{"date":"2026-01-02","current":-25.978102,"twenty":-21.880226,"median":-13.072343,"eighty":-9.298017,"marketCap":1836028338},{"date":"2026-01-09","current":-23.111292,"twenty":-22.280894,"median":-13.196456,"eighty":-9.333606,"marketCap":1633413640},{"date":"2026-01-16","current":-24.532068,"twenty":-22.755262,"median":-13.25865,"eighty":-9.367357,"marketCap":1733828413},{"date":"2026-01-23","current":-26.375919,"twenty":-23.010449,"median":-13.309024,"eighty":-9.375135,"marketCap":1864144474},{"date":"2026-01-30","current":-26.798995,"twenty":-23.217376,"median":-13.467945,"eighty":-9.407045,"marketCap":1894045762},{"date":"2026-02-06","current":-22.258826,"twenty":-24.10394,"median":-13.562826,"eighty":-9.536018,"marketCap":1573164777},{"date":"2026-02-13","current":-23.768006,"twenty":-23.957443,"median":-13.817157,"eighty":-9.627762,"marketCap":1679827580},{"date":"2026-02-20","current":-23.578569,"twenty":-24.004802,"median":-13.914449,"eighty":-9.63308,"marketCap":1666438943},{"date":"2026-02-27","current":-23.99533,"twenty":-24.004802,"median":-13.951438,"eighty":-9.646376,"marketCap":1695893944},{"date":"2026-03-06","current":-20.661282,"twenty":-23.99533,"median":-14.087299,"eighty":-9.713547,"marketCap":1555133402},{"date":"2026-03-13","current":-21.928699,"twenty":-23.824837,"median":-14.227481,"eighty":-9.792228,"marketCap":1650529317},{"date":"2026-03-20","current":-21.217272,"twenty":-23.768006,"median":-14.329335,"eighty":-9.792634,"marketCap":1596981610},{"date":"2026-03-27","current":-22.693932,"twenty":-23.692231,"median":-14.628741,"eighty":-9.859115,"marketCap":1708126851},{"date":"2026-04-02","current":-24.690711,"twenty":-23.779372,"median":-14.699136,"eighty":-9.933573,"marketCap":1858420414},{"date":"2026-04-10","current":-23.249921,"twenty":-23.779372,"median":-14.763927,"eighty":-10.393622,"marketCap":1749975058},{"date":"2026-04-17","current":-27.046193,"twenty":-23.997224,"median":-14.955149,"eighty":-10.519675,"marketCap":2035712822},{"date":"2026-04-24","current":-22.927089,"twenty":-24.052712,"median":-15.059369,"eighty":-10.529177,"marketCap":1725676099},{"date":"2026-05-01","current":-23.210503,"twenty":-24.014274,"median":-15.233234,"eighty":-10.592246,"marketCap":1747008171},{"date":"2026-05-08","current":-25.975372,"twenty":-24.255396,"median":-15.761105,"eighty":-10.607665,"marketCap":1955114312},{"date":"2026-05-15","current":-22.568569,"twenty":-24.314473,"median":-16.442494,"eighty":-10.647042,"marketCap":1931079614},{"date":"2026-05-22","current":-22.030343,"twenty":-24.255396,"median":-16.587573,"eighty":-10.662204,"marketCap":1885026277},{"date":"2026-05-29","current":-22.584399,"twenty":-24.225568,"median":-16.843662,"eighty":-10.799155,"marketCap":1932434124},{"date":"2026-06-05","current":-19.935481,"twenty":-24.091149,"median":-17.056099,"eighty":-10.92148,"marketCap":1705779467},{"date":"2026-06-12","current":-19.022607,"twenty":-24.014274,"median":-17.123032,"eighty":-10.948046,"marketCap":1627669396},{"date":"2026-06-18","current":-19.381425,"twenty":-24.010485,"median":-17.425682,"eighty":-10.97603,"marketCap":1658371620},{"date":"2026-06-26","current":-22.568569,"twenty":-24.001013,"median":-17.729808,"eighty":-11.059188,"marketCap":1931079614},{"date":"2026-07-02","current":-21.972299,"twenty":-23.989729,"median":-17.973475,"eighty":-11.131559,"marketCap":1880059741},{"date":"2026-07-10","current":-23.713619,"twenty":-23.938829,"median":-18.418073,"eighty":-11.16347,"marketCap":2029055830},{"date":"2026-07-17","current":-23.898305,"twenty":-23.898305,"median":-18.702419,"eighty":-11.254892,"marketCap":2044858445},{"date":"2026-07-24","current":-23.249267,"twenty":-23.989729,"median":-18.996224,"eighty":-11.281848,"marketCap":1989323539},{"date":"2026-07-31","current":-24.684537,"twenty":-24.004802,"median":-19.043698,"eighty":-11.288454,"marketCap":2112132437},{"date":"2026-08-07","current":-23.001015,"twenty":-24.109374,"median":-19.37351,"eighty":-11.295102,"marketCap":2239907871},{"date":"2026-08-14","current":-3.036352,"twenty":-24.014274,"median":-19.249507,"eighty":-11.248566,"marketCap":295689089},{"date":"2026-08-21","current":-2.562793,"twenty":-24.014274,"median":-19.009416,"eighty":-10.951574,"marketCap":249572442},{"date":"2026-08-28","current":-2.813501,"twenty":-24.004802,"median":-18.741047,"eighty":-10.656886,"marketCap":273987137},{"date":"2026-09-04","current":-3.13385,"twenty":-23.99533,"median":-18.500988,"eighty":-10.523599,"marketCap":305183693},{"date":"2026-09-09","current":-3.3892,"twenty":-23.984129,"median":-18.377353,"eighty":-10.172905,"marketCap":330050512}],"updateTime":1789093991317},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SION\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634218216","title":"Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026. Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026. Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028. \"We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna,\" said Mike Cloonan, President and Chief Executive Officer of Sionna. \"With both of our clinical stage NBD1 stabilizer programs on track for topline readouts this summer, we remain focused on advancing these first-in-class product candidat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4181","PK","SION","SOC","BK4213","BK4139","CF","BK4585","BK4093","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634561312","title":"Sionna Therapeutics director Peter A. Thompson sells 292,952 shares for $13.37 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634561312","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634561312?lang=en_us&edition=fundamental","pubTime":"2026-05-12 07:14","pubTimestamp":1778541278,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics director Peter A. Thompson reported sales of 292,952 common shares on May 7-11.Shares were sold at prices ranging from $44.58 to $46.22.Beneficial ownership following transactions totaled 2,671,822 shares, held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3n3Zmg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634256305","title":"OrbiMed Advisors disposes 292,952 Sionna Therapeutics shares for $13.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634256305","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634256305?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:59","pubTimestamp":1778540370,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors disclosed sales of 292,952 Sionna Therapeutics common shares from May 7 to May 11 under a 10b5-1 plan.Sales prices ranged from USD 44.58 to USD 46.22 per share.OrbiMed reported 2,671,822 shares beneficially owned following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7PqlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OrbiMed Advisors disposes 292,952 Sionna Therapeutics shares for $13.5 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945051","title":"Sionna Therapeutics Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945051?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:34","pubTimestamp":1777988040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SION/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 09:34 ET (13:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633912441","title":"Sionna Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $53","url":"https://stock-news.laohu8.com/highlight/detail?id=2633912441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633912441?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:23","pubTimestamp":1777980203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nFWN41I0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633911458","title":"Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2633911458","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633911458?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:53","pubTimestamp":1777978426,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics (SION) has an average rating of buy and mean price target of $50.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633997357","title":"Is Sionna Therapeutics (SION) Stock Overvalued After Its Strong 1 Year Run And 6x P/B Multiple","url":"https://stock-news.laohu8.com/highlight/detail?id=2633997357","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633997357?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:20","pubTimestamp":1777962030,"startTime":"0","endTime":"0","summary":"What Sionna Therapeutics Stock Is Telling Investors Right Now\nSionna Therapeutics (SION) has moved quietly on the market, with the stock near $40.45 and mixed recent returns. This gives investors a snapshot of sentiment around this clinical-stage cystic fibrosis specialist.\nSee our latest analysis for Sionna Therapeutics.\nThe picture is mixed, with a recent 1-day share price return of 3.32% and 7-day share price return of 3.16% set against a 90-day share price return decline of 9.06%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sion/sionna-therapeutics/news/is-sionna-therapeutics-sion-stock-overvalued-after-its-stron","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sion/sionna-therapeutics/news/is-sionna-therapeutics-sion-stock-overvalued-after-its-stron","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966503","title":"Sionna Therapeutics initiated with an Outperform at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966503?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:21","pubTimestamp":1777926086,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $53 price target The company’s focus rem...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-initiated-with-an-outperform-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-initiated-with-an-outperform-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631158718","title":"Sionna Therapeutics Is Maintained at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2631158718","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631158718?lang=en_us&edition=fundamental","pubTime":"2026-04-29 02:14","pubTimestamp":1777400040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SION/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2026 14:14 ET (18:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630770733","title":"Sionna Therapeutics price target raised to $63 from $52 at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2630770733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630770733?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:20","pubTimestamp":1777371616,"startTime":"0","endTime":"0","summary":"JonesResearch raised the firm’s price target on Sionna Therapeutics (SION) to $63 from $52 and keeps a Buy rating on the shares after the company c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-price-target-raised-to-63-from-52-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sionna-therapeutics-price-target-raised-to-63-from-52-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630127453","title":"Sionna Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630127453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630127453?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:05","pubTimestamp":1777320349,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics will hold its 2026 annual stockholder meeting online on June 17, 2026.Shareholders will vote on election of four Class II directors with terms running to 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL86h43S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630316157","title":"Sionna Therapeutics Price Target Maintained With a $58.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2630316157","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630316157?lang=en_us&edition=fundamental","pubTime":"2026-04-28 00:50","pubTimestamp":1777308600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SION/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 12:50 ET (16:50 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630984003","title":"Sionna Therapeutics completes enrollment in Phase 2a PreciSION CF trial of SION-719","url":"https://stock-news.laohu8.com/highlight/detail?id=2630984003","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630984003?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:02","pubTimestamp":1777287730,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics completed enrollment in PreciSION CF, a Phase 2a proof-of-concept trial testing SION-719 added to Trikafta in adults with cystic fibrosis.Results have not been presented; topline data are expected in summer 2026.Study aims to show whether SION-719 can improve CFTR function when used on top of current standard of care, while remaining safe and tolerable.Program positions SION-719 as a first-in-class approach targeting the underlying defect linked to the most common CF-causing mutation, supporting Sionna’s strategy to extend benefits beyond existing modulators.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL74dFTv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","NDAQ","SG9999014013.SGD","BK4588","SION","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630398997","title":"Sionna Therapeutics Inc: Anticipates Data From Precision CF Trial in Summer of 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630398997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630398997?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUAQD018:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630139894","title":"Sionna Therapeutics Completes Enrollment in Precision CF Phase 2a Trial Evaluating Nbd1 Stabilizer, Sion-719, Added to Standard of Care in Participants With Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2630139894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630139894?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUAQD018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062322","title":"Sionna director Peter A. Thompson disposes of USD 2.5 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062322","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629062322?lang=en_us&edition=fundamental","pubTime":"2026-04-22 08:43","pubTimestamp":1776818586,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics director Peter A. Thompson reported sales of common stock on April 17-18.Transaction totaled 55,345 shares at prices of USD 44.52 to USD 44.68.Beneficial ownership following transactions was 2,964,774 shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL8TVmL0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629314062","title":"OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $2.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629314062","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629314062?lang=en_us&edition=fundamental","pubTime":"2026-04-22 08:40","pubTimestamp":1776818454,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors LLC, director, sold 55,345 shares of Sionna Therapeutics common stock on April 17-18.Sales were reported at prices of USD 44.68, USD 44.52.Indirect beneficial ownership following transactions was 2,964,774 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6FbmBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $2.5 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628247968","title":"Sionna director Peter A. Thompson disposes of common shares worth $23.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628247968","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628247968?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:15","pubTimestamp":1776381346,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics director Peter A. Thompson reported sales of 510,583 shares of common stock on April 14-16.Transactions were priced at USD 44.51-45.34 per share.Indirect beneficial ownership fell to 3,020,119 shares following the reported sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL4prYcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SION","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628324755","title":"OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $23.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628324755","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628324755?lang=en_us&edition=fundamental","pubTime":"2026-04-17 07:04","pubTimestamp":1776380657,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors, company director, reported sale of 510,583 Sionna Therapeutics common shares on April 14-16.Sales priced between $44.51 and $45.34 per share.Indirect beneficial ownership fell to 3,020,119 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL7CpQlK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OrbiMed Advisors reports Sionna Therapeutics common stock disposal worth $23.1 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626198437","title":"Assessing Sionna Therapeutics (SION) Valuation After Recent Trading And Cystic Fibrosis Pipeline Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2626198437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626198437?lang=en_us&edition=fundamental","pubTime":"2026-04-10 15:22","pubTimestamp":1775805722,"startTime":"0","endTime":"0","summary":"What recent performance says about Sionna Therapeutics\nSionna Therapeutics (SION) has drawn fresh attention after recent trading, with the stock closing at $38.89. Over the past month, the share price return sits near 2%, while the past 3 months are slightly negative.\nSee our latest analysis for Sionna Therapeutics.\nThat 5.25% 1 day share price return stands in contrast to a slightly negative year to date share price return of 0.82%. The 1 year total shareholder return of about 4x hints at...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sion/sionna-therapeutics/news/assessing-sionna-therapeutics-sion-valuation-after-recent-tr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sion/sionna-therapeutics/news/assessing-sionna-therapeutics-sion-valuation-after-recent-tr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SION"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":125,"code":"91000000","status":"200"}]}}